Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (BHC)
NYSE:BHC
RESEARCH TOOLSreports
Bausch Health Companies (BHC) Stock Price & Analysis
2,365 Followers
BHC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.57 - $11.46
Previous Close$7.03
Volume1.60M
Average Volume (3M)3.16M
Market Cap
$2.59B
Enterprise Value$24.96B
Total Cash (Recent Filing)$947.00M
Total Debt (Recent Filing)$22.39B
Price to Earnings (P/E)-5.6
Beta1.11
Next Earnings
Aug 06, 2024EPS Estimate
$0.88Last Dividend Ex-Date
Nov 10, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding366,796,721
10 Day Avg. Volume3,587,642
30 Day Avg. Volume3,155,991
Standard Deviation0.16
R-Squared0.09
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-0.15
Price to Sales (P/S)1.07
Price to Cash Flow (P/CF)1.70
P/FCF Ratio0.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.86
Enterprise Value/Gross Profit2.86
Enterprise Value/Ebitda-80.52
Forecast
1Y Price Target
$10.80Price Target Upside53.19% Upside
Rating ConsensusHold
Number of Analyst Covering6
Bausch Health Companies News
PremiumCompany Announcements
Bausch Health Reports Growth and Milestones
PremiumCompany Announcements
Bausch Health Wins Patent Appeal for XIFAXAN
Bulls Say, Bears Say
Bulls Say
Financial StrategyWith debt levels under control, Bausch Health is positioned to proceed with its planned spin-off, a move that is anticipated to be well-received by the market.
Legal And Patent ProtectionBausch Health's victory in the U.S. Court of Appeals affirms the exclusivity of Xifaxan until 2029, securing its market position against generic competitors.
Stock ValuationThe analyst's Sum of The Parts (SOTP) analysis suggests a potential upside for Bausch Health's stock price, reinforcing a Buy rating with a target of $16.
Bears Say
Corporate Strategy ConcernsUncertainties around the execution and timing of BHC's company separation raise questions about the stock's sole value unlocking mechanism, potentially impacting investor confidence.
Generic CompetitionPrevious settlements with generic manufacturers like Teva, Sandoz, and Sun do not guarantee security against future generic competition, as ongoing litigation with Norwich and potential new filers pose a continuous threat.
Litigation RiskXifaxan's future is at risk due to ongoing additional litigation with Amneal, which could create prolonged uncertainty for investors.
---
Ownership Overview
70.29% Insiders
7.21% Mutual Funds
5.53% Other Institutional Investors
16.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was $5.57 and its highest was $11.46 in the past 12 months.
What is Bausch Health Companies’s market cap?
Currently, no data Available
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Aug 06, 2024 which is in 89 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on May 02, 2024. The company reported $0.629 earnings per share for the quarter, missing the consensus estimate of $0.679 by -$0.05.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of $1 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is $0.88.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 366,796,720 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of $0.629 in its last earnings report, missing expectations of $0.679. Following the earnings report the stock price went down -7.543%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Among the largest hedge funds holding Bausch Health Companies’s share is Carl Icahn C. It holds Bausch Health Companies’s shares valued at 278M.
---
Bausch Health Companies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.80 (53.19% Upside)
$10.80 (53.19% Upside)
Blogger Sentiment
Bullish
BHC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.77%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.
---
BHC Company Deck
---
BHC Earnings Call
Q1 2024
0:00 / 0:00
---
BHC Revenue Breakdown
44.64% Pharmaceuticals
22.80% Devices
20.52% OTC
10.96% Branded and Other Generics
1.07% Other
---
BHC Stock 12 Month Forecast
Average Price Target
$10.80
▲(53.19% Upside)
Technical Analysis
Best Analysts Covering BHC
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+20.22%
reiterated a sell rating 3 months ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +20.22% per trade.
---